# TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

> **NCT04512261** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Reva Basho**

## Conditions studied

- Breast Cancer
- Brain Metastases
- HER2-positive Breast Cancer
- CNS Disease

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04512261
- **Lead sponsor:** Reva Basho
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer.
- **Last updated:** 2022-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04512261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04512261, "TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04512261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*